The National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a standard-of-care regimen, bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment ...

Head of Investor Relations Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the ...

Deutsche Bank upgraded Sanofi (SNY) to Hold from Sell with a price target of EUR 100, up from EUR 85, following the company’s “solid” Q4 ...

Sanofi SA (SNY) stock saw a decline, ending the day at $52.15 which represents a decrease of $-0.82 or -1.55% from the prior close of $52.97. The stock opened at $52.84 and touched a low of $52.14 ...

The company projects mid to high single-digit sales growth in 2025 at constant exchange rates, excluding hyperinflation effects, and low double-digit business EPS growth before foreign exchange and ...

Teva Pharmaceutical's Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. See why I ...

Sanofi’s jump in earnings comes with an increased emphasis on R&D and vaccines, plus an eye cast toward M&A to shore up its pipeline.

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

Sanofi has removed a clutch of programs from its clinical pipeline, scratching out entries for its late-phase BTK inhibitor and phase 1 prospects linked to the multibillion-dollar takeovers of Ablynx, ...

Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, 2025 outlook, drug pipeline, ...

Reports Business EPS of EUR 1.31, down 11.0% at CER and down 14.9% reported. Reports Q4 IRFS net sales EUR 10.56B, up 9.1% reported and up ...

Sanofi CFO François Roger signals increased M&A activity, eyes China for innovation, as company expects cash from Opella sale and plans €5B share buyback.